23255-54-1 Usage
Uses
Used in Pharmaceutical Industry:
Dihydro-beta-erythroidine hydrobromide is used as a therapeutic agent for the treatment of nicotine addiction. Its antagonistic effects on nicotinic acetylcholine receptors, specifically α4β2 and α3β2, make it a potential candidate for smoking cessation aids, helping to reduce the rewarding effects of nicotine and potentially easing withdrawal symptoms.
Used in Neurological Disorder Research:
In the field of neurological disorders, dihydro-beta-erythroidine hydrobromide is used as a research tool to investigate the role of nicotinic acetylcholine receptors in various conditions. Its antagonistic properties may provide insights into the development of treatments for disorders where these receptors play a significant role, such as Alzheimer's disease, Parkinson's disease, and schizophrenia.
Used in Drug Development:
Dihydro-beta-erythroidine hydrobromide is utilized in drug development as a lead compound for the creation of new medications targeting nicotinic acetylcholine receptors. Its selectivity and affinity for specific receptor subtypes make it a valuable asset in the design of drugs with fewer side effects and greater efficacy in treating nicotine addiction and related neurological conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 23255-54-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,2,5 and 5 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 23255-54:
(7*2)+(6*3)+(5*2)+(4*5)+(3*5)+(2*5)+(1*4)=91
91 % 10 = 1
So 23255-54-1 is a valid CAS Registry Number.
23255-54-1Relevant academic research and scientific papers
Clementson, Sebastian,Jessing, Mikkel,Pedersen, Henrik,Vital, Paulo,Kristensen, Jesper L.
, p. 8783 - 8786 (2019)
Erythrina alkaloids represent a rich source of complex polycyclic, bioactive natural products. In addition to their sedative and hypotensive effect, their curare-like activity and structural framework have made them attractive targets for synthetic and medicinal chemists. (+)-Dihydro-β-erythroidine (DHβE), the most potent nicotine acetylcholine receptor antagonist (nAChR) of the Erythrina family, is synthesized for the first time in 13 steps from commercially available material.
Development of a Divergent Route to Erythrina Alkaloids
Clementson, Sebastian,Jessing, Mikkel,Kristensen, Jesper L.,Vital, Paulo J.
, p. 327 - 333 (2020/02/27)
Erythrina alkaloids were identified at the end of the 19th century and today, more than 100 members of the erythrinane family have been isolated. They are characterized by a unique tetracyclic, α-tertiary spiroamine scaffold. Herein we detail our efforts towards the development of a divergent enantioselective synthesis of (+)-dihydro-β-erythroidine (DHβE) - one of the most prominent members of this intriguing family of natural products. 1 Introduction 2 Synthetic Strategy 2.1 First Generation 2.2 Second Generation 2.3 Third Generation 2.3.1 Radical Endgame 2.3.2 Completion of the Total Synthesis 3 Conclusion.
